Drug pricing policy just got a lot more complicated, with major implications for patients' access to therapies, both now and in the future.

So far, patient communities are responding in very different ways. Some have already sounded the alarm. Others are ‘waiting and watching’. And many more may seem to have little idea that this might affect them in unprecedented ways. Yet, invariably, it will.

That's why we're tackling this topic across a multi-part series of our PMC (Patient Movement Catalyst ) Pulse and planning a Leadership Hub / virtual Patient Engagement Open Forum (PEOF).

First, we start this month with our PMC Pulse covering the essentials: why patients should know what MFN is and how it matters to them.

Second, we'll dive deeper in next month’s PMC Pulse looking at what stakeholders are already doing, and how we can work together to ensure patients' access to therapies is safeguarded –not eroded– in the future.

Then, in November, we'll bring the community together through a virtual PEOF-hosted ‘PMC Leadership Hub’ to co-create shared actions and potential solutions. So: save the date now! November 10th - afternoon time (CET) to be confirmed soon.

But now: from steep tariff cliffs to early signs of delayed drug launches. From market analysts questioning real-world savings to cancer patients sounding alarms. This month’s PMC Pulse brings you the facts, the evidence, the reactions, and the open questions we’ll tackle next.

PAN is a member of The Synergist, which runs PMC. We encourage you to follow PMC on LinkedIn.